Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia
CONCLUSION: CP-CML patients treated with different TKIs (ponatinib, bosutinib, imatinib, dasatinib, and nilotinib) did not have different incidence of cardiovascular events (MACE, AOEs, VTEs) in this small cohort of real-world patients with ≥6-month of follow-up. The results were consistent among patients with prior use of one and two TKI types.DisclosuresLevy: Takeda (Millennium Pharmaceuticals, Inc.): Consultancy. Xie: STATinMED Research: Employment. Wang: STATinMED Research: Employment. Neumann: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Srivastava: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Naranjo: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Zhang: STATinMED Research: Employment. Dalal: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA: Employment, Equity Ownership.
Source: Blood - Category: Hematology Authors: Levy, M. Y., Xie, L., Wang, Y., Neumann, F., Srivastava, S., Naranjo, D., Zhang, Q., Dalal, M. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster II Source Type: research
More News: Anemia | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Leukemia | Chronic Myeloid Leukaemia | Databases & Libraries | Diabetes | Employment | Endocrinology | Gleevec | Heart | Heart Attack | Hematology | Hemorrhagic Stroke | Hypertension | Ischemic Stroke | Leukemia | Nilotinib | Pulmonary Thromboembolism | Stroke | Study | Tasigna | Thrombosis